AstraZeneca has completed its acquisition of Takeda’s core respiratory business, in a move which the drug giant says will be accretive to its 2016 earnings.
Under the $575-million deal, announced back in December, AZ has taken ownership of three core respiratory medicines, which pulled in annual sales of $198 million (excluding existing AZ sales from roflumilast) for the period ending in March 2015 and 200 Takeda employees.
The deal expands AZ’ rights to roflumilast (marketed as Daliresp in the US and Daxas in other countries), the only approved oral PDE4 inhibitor for the treatment of chronic obstructive pulmonary disease (COPD).
AZ has marketed Daliresp in the US since the first quarter of 2015, taking full global rights under its wing will support the firm’s respiratory franchise and complement its portfolio of treatments for severe COPD, as well as access to other marketed respiratory medicines and early pipeline products.
AZ also announced that it has now completed the divestment of global rights to Imdur, outside the US, to China Medical System Holdings Ltd and its associated company, Tibet Rhodiola Pharmaceutical Holding, for which it will receive $190 million.
Imdur is an oral extended-release formulation of isosorbide mononitrate indicated for the prevention of angina pectoris due to coronary artery disease.
